Sezary Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

Lambrolizumab in Treating Patients With Relapsed or Refractory Stage IIB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions:   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary SyndromeInterventions:   Biological: pembrolizumab;   Other: laboratory biomarker analysisSponsor:   National Cancer Institute (NCI)Not yet recruiting - verified April 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2014 Category: Research Source Type: clinical trials

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IIB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions:   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary SyndromeInterventions:   Biological: pembrolizumab;   Other: laboratory biomarker analysisSponsor:   National Cancer Institute (NCI)Recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2014 Category: Research Source Type: clinical trials